ADC Therapeutics restructures to focus on ZYNLONTA
- ADC Therapeutics (NYSE:ADCT) announced a strategic reorganization focused on its ZYNLONTA franchise and related clinical trials.
- The plan includes an estimated 17% workforce reduction, targeting about $10 million in annual savings.
- The company expects its cash runway to extend into 2028 following the restructuring.
ADC Therapeutics (NYSE:ADCT) announced a strategic reorganization aimed at prioritizing its ZYNLONTA franchise and advancing key clinical programs including LOTIS-5 and LOTIS-7.
The company said the restructuring reflects a sharper focus on its late-stage oncology pipeline as it adjusts its operating structure to align with development priorities.
The plan includes an estimated 17% reduction in workforce, expected to generate about $10 million in annualized savings and approximately $3 million in one-time restructuring charges.
ADC Therapeutics also said the changes are designed to extend its cash runway into 2028, supporting ongoing clinical development and operational flexibility.
The company continues to concentrate resources on its ZYNLONTA franchise, particularly ongoing LOTIS clinical trials that are central to its oncology strategy.
The restructuring highlights ongoing cost-control measures in biotech firms as they balance clinical pipeline investment with longer-term financial sustainability.Meta Title
